- Home
- ANGO vs KMDA Comparison
ANGO vs KMDA Comparison
Compare ANGO & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANGO
- KMDA
- Stock Information
- Founded
- ANGO 1988
- KMDA 1990
- Country
- ANGO United States
- KMDA Israel
- Employees
- ANGO N/A
- KMDA N/A
- Industry
- ANGO Medical/Dental Instruments
- KMDA Biotechnology: Pharmaceutical Preparations
- Sector
- ANGO Health Care
- KMDA Health Care
- Exchange
- ANGO Nasdaq
- KMDA Nasdaq
- Market Cap
- ANGO 439.5M
- KMDA 380.7M
- IPO Year
- ANGO 2004
- KMDA N/A
- Fundamental
- Price
- ANGO $9.11
- KMDA $6.84
- Analyst Decision
- ANGO Strong Buy
- KMDA Strong Buy
- Analyst Count
- ANGO 2
- KMDA 3
- Target Price
- ANGO $14.00
- KMDA $14.67
- AVG Volume (30 Days)
- ANGO 330.9K
- KMDA 57.1K
- Earning Date
- ANGO 04-02-2025
- KMDA 05-14-2025
- Dividend Yield
- ANGO N/A
- KMDA 2.90%
- EPS Growth
- ANGO N/A
- KMDA 66.67
- EPS
- ANGO N/A
- KMDA 0.25
- Revenue
- ANGO $283,320,000.00
- KMDA $160,953,000.00
- Revenue This Year
- ANGO N/A
- KMDA $14.01
- Revenue Next Year
- ANGO $6.35
- KMDA $9.24
- P/E Ratio
- ANGO N/A
- KMDA $27.95
- Revenue Growth
- ANGO N/A
- KMDA 12.93
- 52 Week Low
- ANGO $5.47
- KMDA $4.74
- 52 Week High
- ANGO $13.50
- KMDA $9.15
- Technical
- Relative Strength Index (RSI)
- ANGO 46.41
- KMDA 57.13
- Support Level
- ANGO $8.55
- KMDA $6.60
- Resistance Level
- ANGO $9.68
- KMDA $7.10
- Average True Range (ATR)
- ANGO 0.36
- KMDA 0.16
- MACD
- ANGO -0.02
- KMDA 0.06
- Stochastic Oscillator
- ANGO 46.28
- KMDA 65.33
About ANGO AngioDynamics Inc.
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
About KMDA Kamada Ltd.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.